Latest1 information on COVID-19
©2022 Stanford Medicine
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
Not Recruiting
Trial ID: NCT02216409
Purpose
The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in
participants with solid tumors.
Official Title
A First-in-Human Phase 1 Dose Escalation Trial of Hu5F9-G4 in Patients With Advanced Solid Malignancies
Stanford Investigator(s)
A. Dimitrios Colevas, MD
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
Heather Wakelee
Professor of Medicine (Oncology)
Youn H Kim, MD
The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology)
Eligibility
Inclusion Criteria:
Patients with histologically or cytologically confirmed advanced solid malignancy or
Lymphoma
Relapsed or refractory disease after at least 1 prior systemic treatment for the primary
malignancy and not a candidate for other curative treatment.
Adequate hematologic status
Adequate coagulation function
Adequate hepatic function
Adequate renal function
Exclusion Criteria:
Known primary tumors of central nervous system disease
Known active brain metastases
Known cardiopulmonary disease
Intervention(s):
drug: Hu5F9-G4
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
1-650-498-7061